Crescent Capital bought what was hospital owner Healthscope's Australian pathology business for $105 million to create Australian Clinical Labs in 2015. AFR
The group is Australia's third-biggest pathology services provider with $443 million in revenue last financial year and an estimated 13.1 per cent market share, according to data collector IBISWorld. AFR
It also comes amid a rollercoaster ride for the country's pathology and radiology groups. Volumes were heavily affected in March and April as private hospitals and doctors cut back on non-emergency services. However, they have sprung back to life in recent months. AFR
ACL Price at posting:
$3.42 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)